Phytochemicals in Alzheimer disease: The development of clinical trials

Joseph Quinn, Jeffrey Kaye, Thomas Montine, Robert Stackman

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Polyphenolics and other phytochemicals may have a role in the prevention or treatment of Alzheimer disease. Targets of therapy in Alzheimer disease include neurotransmitter deficits, beta amyloid neurotoxicity, oxidative damage, and inflammation, to name a few. Challenges to the development of phytochemical and other neuroprotectant therapy in Alzheimer disease include the inability to measure pathology in living patients and the challenge of detecting modification of an indolent disease course. These challenges are partially surmounted by the use of animal models and of biomarkers of disease. This review describes currently available animal models and biomarkers and surveys clinical trials of phytochemical therapies that are recently completed or currently under way. Both animal studies and clinical trials of Ginkgo biloba are described, as well as a trial of Uncaria tomentosa that has not been previously reported.

Original languageEnglish (US)
Pages (from-to)64-73
Number of pages10
JournalPharmaceutical Biology
Volume42
Issue numberSUPPL.
DOIs
StatePublished - 2004

Fingerprint

Phytochemicals
Alzheimer disease
phytopharmaceuticals
clinical trials
Alzheimer Disease
Clinical Trials
therapeutics
biomarkers
Uncaria tomentosa
animal models
Animals
Biomarkers
Cat's Claw
Ginkgo biloba
neurotoxicity
amyloid
neurotransmitters
Animal Disease Models
disease course
polyphenols

Keywords

  • Alzheimer disease
  • Antioxidants
  • Oxidative stress
  • Polyphenolics

ASJC Scopus subject areas

  • Plant Science
  • Medical Laboratory Technology
  • Clinical Biochemistry
  • Pharmacology
  • Drug Discovery
  • Pharmaceutical Science
  • Complementary and alternative medicine
  • Molecular Medicine

Cite this

Phytochemicals in Alzheimer disease : The development of clinical trials. / Quinn, Joseph; Kaye, Jeffrey; Montine, Thomas; Stackman, Robert.

In: Pharmaceutical Biology, Vol. 42, No. SUPPL., 2004, p. 64-73.

Research output: Contribution to journalArticle

Quinn, Joseph ; Kaye, Jeffrey ; Montine, Thomas ; Stackman, Robert. / Phytochemicals in Alzheimer disease : The development of clinical trials. In: Pharmaceutical Biology. 2004 ; Vol. 42, No. SUPPL. pp. 64-73.
@article{5c7cc974273749daa7219599c1aad4bb,
title = "Phytochemicals in Alzheimer disease: The development of clinical trials",
abstract = "Polyphenolics and other phytochemicals may have a role in the prevention or treatment of Alzheimer disease. Targets of therapy in Alzheimer disease include neurotransmitter deficits, beta amyloid neurotoxicity, oxidative damage, and inflammation, to name a few. Challenges to the development of phytochemical and other neuroprotectant therapy in Alzheimer disease include the inability to measure pathology in living patients and the challenge of detecting modification of an indolent disease course. These challenges are partially surmounted by the use of animal models and of biomarkers of disease. This review describes currently available animal models and biomarkers and surveys clinical trials of phytochemical therapies that are recently completed or currently under way. Both animal studies and clinical trials of Ginkgo biloba are described, as well as a trial of Uncaria tomentosa that has not been previously reported.",
keywords = "Alzheimer disease, Antioxidants, Oxidative stress, Polyphenolics",
author = "Joseph Quinn and Jeffrey Kaye and Thomas Montine and Robert Stackman",
year = "2004",
doi = "10.1080/138802090893531",
language = "English (US)",
volume = "42",
pages = "64--73",
journal = "Pharmaceutical Biology",
issn = "1388-0209",
publisher = "Informa Healthcare",
number = "SUPPL.",

}

TY - JOUR

T1 - Phytochemicals in Alzheimer disease

T2 - The development of clinical trials

AU - Quinn, Joseph

AU - Kaye, Jeffrey

AU - Montine, Thomas

AU - Stackman, Robert

PY - 2004

Y1 - 2004

N2 - Polyphenolics and other phytochemicals may have a role in the prevention or treatment of Alzheimer disease. Targets of therapy in Alzheimer disease include neurotransmitter deficits, beta amyloid neurotoxicity, oxidative damage, and inflammation, to name a few. Challenges to the development of phytochemical and other neuroprotectant therapy in Alzheimer disease include the inability to measure pathology in living patients and the challenge of detecting modification of an indolent disease course. These challenges are partially surmounted by the use of animal models and of biomarkers of disease. This review describes currently available animal models and biomarkers and surveys clinical trials of phytochemical therapies that are recently completed or currently under way. Both animal studies and clinical trials of Ginkgo biloba are described, as well as a trial of Uncaria tomentosa that has not been previously reported.

AB - Polyphenolics and other phytochemicals may have a role in the prevention or treatment of Alzheimer disease. Targets of therapy in Alzheimer disease include neurotransmitter deficits, beta amyloid neurotoxicity, oxidative damage, and inflammation, to name a few. Challenges to the development of phytochemical and other neuroprotectant therapy in Alzheimer disease include the inability to measure pathology in living patients and the challenge of detecting modification of an indolent disease course. These challenges are partially surmounted by the use of animal models and of biomarkers of disease. This review describes currently available animal models and biomarkers and surveys clinical trials of phytochemical therapies that are recently completed or currently under way. Both animal studies and clinical trials of Ginkgo biloba are described, as well as a trial of Uncaria tomentosa that has not been previously reported.

KW - Alzheimer disease

KW - Antioxidants

KW - Oxidative stress

KW - Polyphenolics

UR - http://www.scopus.com/inward/record.url?scp=11844305626&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=11844305626&partnerID=8YFLogxK

U2 - 10.1080/138802090893531

DO - 10.1080/138802090893531

M3 - Article

AN - SCOPUS:11844305626

VL - 42

SP - 64

EP - 73

JO - Pharmaceutical Biology

JF - Pharmaceutical Biology

SN - 1388-0209

IS - SUPPL.

ER -